Search

everythinglearnresearchcommunity

for

Search:↓

Dimethyl fumarate speeds up wound healing in IL-36Ra deficient mice by reducing NET formation and oxidative stress.

Targeting mTOR in myeloid cells may help reduce psoriasis symptoms.

Expanding CD4+ Tregs can stop hair loss in alopecia areata.

People with severe hair loss have higher levels of a protein called interleukin 17 in their blood.

Retinoids increase steroid sulfatase activity in leukemia cells through RARα/RXR and involves certain pathways like phosphoinositide 3-kinase and ERK-MAP kinase.

Alopecia areata patients have more activated T cells in their blood, which may help in developing treatments.

IL-1 signaling is crucial for hair follicle stem cell growth and wound healing.

Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.

A substance called miR-1246 may help treat severe hair loss by reducing certain immune cell activities.

Certain genes are linked to the risk of developing Alopecia Areata.

A protein called lfTSLP is important in causing allergic and other skin diseases and could be a target for treatment.

Hair follicles produce IL-7, which is essential for certain skin lymphoma cells to survive.

FCER1A and RGS1 may help diagnose and treat systemic lupus erythematosus.

Contact immunotherapy can change immune responses in alopecia areata, suggesting new treatment targets.

LL-37 helps stem cells grow and move, aiding tissue regeneration and hair growth.

Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.

Vδ1+ T-cells in the skin contribute to hair loss in alopecia areata and could be targeted for treatment.

hsa-miR-193a-5p may help diagnose and treat alopecia areata.

A new type of nerve cell involved in itch perception was discovered.

IL-1 alpha stops hair follicle growth and hair production.

Certain genetic variations can make people more likely to experience hair loss and low white blood cell count from azathioprine.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

PD‐L1 and PD‐L2 may not effectively control immune activation in alopecia areata.

The study identified key immune cell differences between mild and severe alopecia areata.

NKG2D+CD4+ T cells are higher in alopecia areata patients and may be involved in the disease.

Aldesleukin can treat certain cancers and increase HIV patient CD4+ counts but often causes severe side effects.

Psoriasis may be chronic because it lacks certain immune system controls that prevent overreaction.

A new mutation in the TMEM173 gene and a risk allele in IFIH1 cause a unique set of immune-related symptoms.